Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

• Naltrexone + Bupropion is FDA approved for chronic weight management. (FDA, 2014)

• Common side effects of Contrave™ include dry mouth, constipation, headaches, vomiting, and dizziness.

• The minimum FDA requirement for placebo-corrected weight loss is 5%. Though contrave met this minimum requirement, there were initial concerns about CV safety.

• Relative contraindication in uncontrolled HTN, seizure disorder, chronic opioid use, bulimia, or anorexia nervosa.

Infographic

Reference

Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Aug 21;376(9741):594. Erratum in: Lancet. 2010 Oct 23;376(9750):1392.

About the author 

MyEndoConsult

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


Videos

  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates
>